...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab
【24h】

Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab

机译：单克隆抗体在多发性硬化症中的治疗应用：关注阿仑单抗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Recent progress in the treatment of multiple sclerosis (MS) is significant, and the potential of monoclonal antibodies (mAbs) for the treatment of MS has been highlighted. Natalizumab demonstrated a high level of efficacy for MS and is the first mAb to be approved for treatment of MS. Clinical trials of several types of mAbs for treatment of MS are in progress, and mAbs are expected to become the new choice of treatment for MS. Alemtuzumab is one of the most promising mAbs for treatment for MS, despite some side effects to be considered such as autoimmune hyperthyroidism, Goodpasture’s syndrome, and autoimmune idiopathic thrombocytopenic purpura. Any therapeutic agents for MS may carry risks of short- or long-term side effects; however, information regarding the long-term side effects of these new agents is lacking. Long-term adverse effects can often be recognized after the approval of agents. Here, recent progress on mAbs for the treatment of MS is reviewed, with a focus on alemtuzumab.
机译：摘要：在多发性硬化症（MS）的治疗方面，最近的进展是显着的，并且单克隆抗体（mAbs）在治疗MS中的潜力也得到了强调。纳他珠单抗对MS表现出高水平的疗效，并且是首个被批准用于MS治疗的mAb。几种用于治疗MS的mAb的临床试验正在进行中，并且mAb有望成为MS治疗的新选择。尽管考虑到一些副作用，例如自身免疫性甲状腺功能亢进症，Goodpasture综合征和自身免疫性特发性血小板减少性紫癜，Alemtuzumab是治疗MS最有前途的mAb之一。任何用于MS的治疗药物都可能具有短期或长期副作用的风险;但是，缺乏有关这些新药的长期副作用的信息。在代理商批准后，通常可以识别出长期不良反应。在这里，综述了mAb用于治疗MS的最新进展，重点是阿仑单抗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号